These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31965746)

  • 21. Baroreflex activation therapy: a new treatment option for heart failure with reduced ejection fraction.
    Halbach M; Hickethier T; Madershahian N; Müller-Ehmsen J
    Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1465-9. PubMed ID: 25382103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction".
    Oliveira M
    Rev Port Cardiol; 2015 Dec; 34(12):795-7. PubMed ID: 27099884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updates on Baroreflex Activation Therapy and Vagus Nerve Stimulation for Treatment of Heart Failure With Reduced Ejection Fraction.
    Babar N; Giedrimiene D
    Cardiol Res; 2022 Feb; 13(1):11-17. PubMed ID: 35211219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of neurohormonal antagonists on blood pressure in patients with heart failure with reduced ejection fraction (HFrEF): a systematic review protocol.
    Guggilla RK; Sowa PM; Jamiolkowski J; Sinnadurai S; Amin A; Kaminski KA
    Syst Rev; 2020 Aug; 9(1):194. PubMed ID: 32838804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study.
    Gronda E; Seravalle G; Brambilla G; Costantino G; Casini A; Alsheraei A; Lovett EG; Mancia G; Grassi G
    Eur J Heart Fail; 2014 Sep; 16(9):977-83. PubMed ID: 25067799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.
    Bisognano J; Schneider JE; Davies S; Ohsfeldt RL; Galle E; Stojanovic I; Deering TF; Lindenfeld J; Zile MR
    BMC Cardiovasc Disord; 2021 Mar; 21(1):155. PubMed ID: 33771104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy.
    Nottebohm PI; Dumitrescu D; Hamacher S; Hohmann C; Madershahian N; Baldus S; Reuter H; Halbach M
    Ther Adv Cardiovasc Dis; 2022; 16():17539447221131203. PubMed ID: 36305639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.
    Ruddy JM; Kroman A; Baicu CF; Zile MR
    Heart Fail Clin; 2024 Jan; 20(1):39-50. PubMed ID: 37953020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
    Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
    Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
    Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
    BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oscillatory Pattern of Sympathetic Nerve Bursts Is Associated With Baroreflex Function in Heart Failure Patients With Reduced Ejection Fraction.
    Toschi-Dias E; Montano N; Tobaldini E; Trevizan PF; Groehs RV; Antunes-Correa LM; Nobre TS; Lobo DM; Sales ARK; Ueno-Pardi LM; de Matos LDNJ; Oliveira PA; Braga AMFW; Alves MJNN; Negrão CE; Rondon MUPB
    Front Neurosci; 2021; 15():669535. PubMed ID: 34531714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New Technologies and Devices of Heart Failure with Reduced Ejection Fraction].
    Fan X; He Q; Feng S; Wang J
    Zhongguo Yi Liao Qi Xie Za Zhi; 2023 Feb; 47(2):185-189. PubMed ID: 37096473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baroreflex activation therapy in advanced heart failure therapy: insights from a real-world scenario.
    Guckel D; Eitz T; El Hamriti M; Braun M; Khalaph M; Imnadze G; Fink T; Sciacca V; Sohns C; Sommer P; Nölker G
    ESC Heart Fail; 2023 Feb; 10(1):284-294. PubMed ID: 36208130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.
    Fisher SA; Brunskill SJ; Doree C; Mathur A; Taggart DP; Martin-Rendon E
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007888. PubMed ID: 24777540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the efficacy and acceptability of Chinese herbal medicine in adult patients with heart failure and reduced ejection fraction: study protocol for a systematic review and network meta-analysis.
    Liu J; Lu JJ; Zhou K; Wan J; Li Y; Cui XY; Gao Q; Huang YC; Li SN; Dong QZ; Lin Q
    BMJ Open; 2018 Jun; 8(6):e015678. PubMed ID: 29921675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review: cardiac resynchronization in patients with symptomatic heart failure.
    McAlister FA; Ezekowitz JA; Wiebe N; Rowe B; Spooner C; Crumley E; Hartling L; Klassen T; Abraham W
    Ann Intern Med; 2004 Sep; 141(5):381-90. PubMed ID: 15353430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Bendary A; Bendary M; Salem M
    Heart Fail Rev; 2019 Mar; 24(2):245-254. PubMed ID: 30317416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of baroreflex activation therapy for treatment of resistant hypertension: a systematic review and meta-analysis.
    Chunbin W; Fu S; Jing H
    Clin Exp Hypertens; 2018; 40(6):501-508. PubMed ID: 29624472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction.
    Georgakopoulos D; Little WC; Abraham WT; Weaver FA; Zile MR
    J Card Fail; 2011 Feb; 17(2):167-78. PubMed ID: 21300307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF.
    Zile MR; Abraham WT; Lindenfeld J; Weaver FA; Zannad F; Graves T; Rogers T; Galle EG
    Am Heart J; 2018 Oct; 204():139-150. PubMed ID: 30118942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.